His primary areas of study are Biochemistry, Small molecule, High-throughput screening, Structure–activity relationship and Drug discovery. The study of Biochemistry is intertwined with the study of Stereochemistry in a number of ways. His Small molecule research includes themes of Base excision repair, Molecular biology, FOXM1, Forkhead Transcription Factors and Transcription.
His High-throughput screening research is multidisciplinary, incorporating perspectives in Autofluorescence, Nanotechnology, Beta-Lactamase Inhibitors, Fluorescence spectrometry and Combinatorial chemistry. His work deals with themes such as Toxicity, Stress response pathway, Molecular model and Pharmacology, which intersect with Structure–activity relationship. His research in Drug discovery intersects with topics in Computational biology, Cell function and Molecular targets.
Anton Simeonov mainly investigates Biochemistry, Small molecule, Computational biology, Drug discovery and High-throughput screening. Anton Simeonov interconnects Molecular biology and Stereochemistry in the investigation of issues within Biochemistry. Anton Simeonov combines subjects such as DNA damage and Cell biology with his study of Small molecule.
In most of his Computational biology studies, his work intersects topics such as High-Throughput Screening Assays.
Computational biology, Drug, Pharmacology, Drug repositioning and Cancer research are his primary areas of study. The study incorporates disciplines such as Viral replication, In silico, Small molecule and Proteasome in addition to Computational biology. His Small molecule study incorporates themes from Phosphatidylinositol, Kinase, Phosphatidylinositol 5-phosphate, Structure–activity relationship and Drug discovery.
His research in the fields of Combination therapy overlaps with other disciplines such as Camostat. His Cytotoxicity research entails a greater understanding of Biochemistry. The concepts of his Biochemistry study are interwoven with issues in Schistosomiasis and Praziquantel.
His primary areas of investigation include Drug repositioning, Severe acute respiratory syndrome coronavirus 2, Pharmacology, Clinical trial and Coronavirus. His research integrates issues of Cytopathic effect and Approved drug in his study of Drug repositioning. His work deals with themes such as Pandemic and Emergency Use Authorization, which intersect with Severe acute respiratory syndrome coronavirus 2.
His Pharmacology research is multidisciplinary, relying on both Proteases, Gabexate, Nafamostat, Protease and Viral entry. In his work, Biochemistry is strongly intertwined with In vivo, which is a subfield of Cell culture. He interconnects Luciferase, Chemical structure and High-throughput screening in the investigation of issues within Computational biology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries.
James Inglese;Douglas S. Auld;Ajit Jadhav;Ronald L. Johnson.
Proceedings of the National Academy of Sciences of the United States of America (2006)
High-throughput screening assays for the identification of chemical probes
James Inglese;Ronald L Johnson;Anton Simeonov;Menghang Xia.
Nature Chemical Biology (2007)
Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions
Susanne A.I. Seidel;Patricia M. Dijkman;Wendy A. Lea;Geert van den Bogaart.
Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
Richard T. Eastman;Jacob S. Roth;Jacob S. Roth;Kyle R. Brimacombe;Anton Simeonov.
ACS central science (2020)
Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen
Miao Xu;Emily M. Lee;Zhexing Wen;Yichen Cheng.
Nature Medicine (2016)
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells
Lesley A. Mathews Griner;Rajarshi Guha;Paul Shinn;Ryan M. Young.
Proceedings of the National Academy of Sciences of the United States of America (2014)
A high-throughput screen for aggregation-based inhibition in a large compound library.
Brian Y. Feng;Anton Simeonov;Ajit Jadhav;Kerim Babaoglu.
Journal of Medicinal Chemistry (2007)
Gene expression analysis identifies global gene dosage sensitivity in cancer
Rudolf S. N. Fehrmann;Juha M. Karjalainen;Małgorzata Krajewska;Harm-Jan Westra.
Nature Genetics (2015)
Fluorescence Polarization Assays in Small Molecule Screening
Wendy A Lea;Anton Simeonov.
Expert Opinion on Drug Discovery (2011)
Identification of oxadiazoles as new drug leads for the control of schistosomiasis
Ahmed A Sayed;Anton Simeonov;Craig J Thomas;James Inglese.
Nature Medicine (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: